Spots Global Cancer Trial Database for jmml
Every month we try and update this database with for jmml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | NCT05849662 | Leukemia, Juven... JMML JCML Neurofibromatos... CBL Syndrome | Trametinib Azacitidine Fludarabine Cytarabine | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | NCT05849662 | Leukemia, Juven... JMML JCML Neurofibromatos... CBL Syndrome | Trametinib Azacitidine Fludarabine Cytarabine | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | NCT00669890 | Acute Myeloid L... Juvenile Myelom... Myelodysplastic... | Gemtuzumab Ozog... Busulfan Cyclophosphamid... Thymoglobulin Tacrolimus Mycophenolate M... Methotrexate | - 30 Years | New York Medical College | |
| Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | NCT00509600 | Leukemia | Etanercept | 6 Months - 18 Years | M.D. Anderson Cancer Center | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | NCT00669890 | Acute Myeloid L... Juvenile Myelom... Myelodysplastic... | Gemtuzumab Ozog... Busulfan Cyclophosphamid... Thymoglobulin Tacrolimus Mycophenolate M... Methotrexate | - 30 Years | New York Medical College | |
| Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood | NCT00662090 | Myelodysplastic... Juvenile Myelom... | - 215 Months | University Hospital Freiburg | ||
| Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | NCT02333058 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Juvenile Myelom... | Treosulfan | 28 Days - 17 Years | medac GmbH | |
| Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | NCT02333058 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Juvenile Myelom... | Treosulfan | 28 Days - 17 Years | medac GmbH | |
| Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | NCT00796562 | MDS Leukemias Lymphomas | Busulfan Cyclophosphamid... Total body irra... | 6 Months - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
